by Peter Ciszewski | Jun 18, 2020
Robert Rifkin, MD of the Rocky Mountain Cancer Center in Denver CO describes the real-world study he presented at the European Hematology Association (EHA) Annual Meeting that used fitbit and quality of life measures to assess whether multiple myeloma patients...
by Peter Ciszewski | Jun 17, 2020
The U.S. Food and Drug Administration (FDA) has approved Ilaris (canakinumab) to treat Still’s disease. Still’s disease is a rare autoinflammatory disease of unknown origin. It is similar to systemic juvenile idiopathic arthritis (SJIA), another rare autoimmune...
by Peter Ciszewski | Jun 16, 2020
Ozlem Goker-Alpan, MD provides a summary of research presented at WORLDSymposium 2020 focused on the pain associated with Fabry disease. Fabry disease an X-linked genetic disorder that leads to the buildup of globotriaosylceramide in the body’s cells that can...
by Peter Ciszewski | Jun 15, 2020
Riam Shammaa, MD, Founder and CEO of INTELLiSTEM Technologies, talks about the some of the vaccines in development targeting the coronavirus. As Dr. Shammaa explains in this video, numerous companies are likely needed to develop multiple vaccines to make sure...
by Peter Ciszewski | Jun 12, 2020
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a rare autoimmune disease of the central nervous system...
